NEWS
Long-term Follow-up Confirms Breast Cancer Risk Reduction with Raloxifene
The drugs raloxifene (Evista) and tamoxifen both substantially reduce the risk of breast cancer in women at high risk for the disease, but raloxifene causes fewer and less-severe side effects, according to the long-term results of a large breast cancer prevention trial presented yesterday at the American Association for Cancer Research (AACR) annual meeting in Washington, DC. Read more > >
MicroRNAs Linked to Trastuzumab Resistance, Brain Metastases
Studies suggest potential diagnostic, therapeutic opportunitiesDiabetes Drug Metformin Prevents Lung Tumors in Mice
A planned clinical trial will test the drug in smokers at high risk for the diseaseCancer Risk Tools May Need Regular Recalibration
NCI’s breast cancer risk model will be updated to account for changing population trendsProfiling Airway Cells May Identify Smokers at Highest Risk of Cancer
The PI3K pathway may be activated early in the development of some lung cancersPeptide Helps Chemotherapy Penetrate Deep into Tumors
Increases in drug potency were seen in mice without increases in toxicity
COMMENTARY
Director's Update: An Unexpected Opportunity,
a Welcome Honor
The Director’s Update for this issue was taken from the remarks delivered by NCI Director Dr. John E. Niederhuber on Sunday, April 18, at the 101st Annual Meeting of the American Association for Cancer Research (AACR) in Washington, DC. Dr. Niederhuber was presented with the AACR Award for Distinguished Public Service. Read more > >
Guest Commentary by Dr. Carolyn Clancy: Focusing the Research Enterprise on the Patient
The director of AHRQ discusses how patient-centered research improves the quality of care for cancer patients Read more > >
IN DEPTH
Trial Makes Push Toward More Individualized Lung Cancer Therapy
Study incorporates novel statistical model to guide assignment of therapies for patients
Genome Study of Aggressive Breast Cancer Yields Clues to Metastasis
Researchers sequenced four DNA samples from a woman with the basal-like subtype
Featured Clinical Trial: Pioglitazone for Oral Premalignant Lesions
Can a diabetes drug treat mouth sores before they become oral cancer?
IOM Committee Recommends Overhaul of NCI Clinical Trials Cooperative Group Program
Report outlines four goals to guide improvement efforts
UPDATES
FDA Update
- Erlotinib Approved as Maintenance Therapy for Non-small Cell Lung Cancer
- Long-term Shortage of Cancer Drug Mustargen Expected
- Changes Announced in Approval Process for Certain Radiation Therapy Devices
Legislative Update
- House Committee Convenes Hearing on Smokeless Tobacco
Cancer.gov Update
- NCI Issues Updated Cancer Trends Progress Report
- SEER Program Releases New CSR Data
- NCI Launches “New on Cancer.gov” E-mail List
Notes
- New Cancer Signatures Funding
Opportunity Announced - Learn About NCI Resources and Opportunities at BIO International Convention
- NCI and Republic of Croatia Formalize Alliance
- New Cancer Signatures Funding
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
